No influence of propanolol, cyclosporine, adriamycin, and nifedipine in the in vitro labelling of erythrocytes;No influencia de propanolol, ciclosporina, adriamicina y nifedipina en el marcaje in vitro de hematíes

Revista Espanola de Medicina Nuclear

Volumn 21, Issue 1, 2002, Pages 24-27

  Cardoso, V Nascimento ^a   Roca, M ^b   Martin Comin J ^b  

^a UFMG   (Brazil)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Ejection fraction; MUGA; Red blood cell labelling

Indexed keywords

CYCLOSPORIN; DOXORUBICIN; EDETIC ACID; HYPOCHLOROUS ACID; NIFEDIPINE; PROPRANOLOL; RADIOPHARMACEUTICAL AGENT; STANNOUS CHLORIDE; TECHNETIUM; TIN DERIVATIVE; ERYTHROCYTE TC 99M;

ADULT; ARTICLE; CENTRIFUGATION; CHEMISTRY; DRUG EFFECT; ERYTHROCYTE; HUMAN; ISOTOPE LABELING; CELL LABELING; CONTROLLED STUDY; IN VITRO SELECTION; NORMAL HUMAN; RADIOCHEMISTRY; RADIOISOTOPE VENTRICULOGRAPHY;

ADULT; CENTRIFUGATION; CYCLOSPORINE; DOXORUBICIN; EDETIC ACID; ERYTHROCYTES; HUMANS; HYPOCHLOROUS ACID; ISOTOPE LABELING; NIFEDIPINE; PROPRANOLOL; RADIOPHARMACEUTICALS; TECHNETIUM; TIN COMPOUNDS;

EID: 0036479763     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/S0212-6982(02)72028-4     Document Type: Article

References (20)

1. 99mTc in vitro and in vivo. J Nucl Med 1978;19:129-34.
2. 99mTc-labeled red blood cells scintigraphy for the detection and localization of gastrointestinal bleeding sites». Gastroenterol 1982;83(2):394-8.
3. 99mTc: concise communications. J Nucl Med 1982;23:315-7.
4. Fonseca JF, Braga ACS, Oliveira MB, Ribeiro CR, Reinenger IW, et al. Drug interaction in the labeling of red blood cells (abstracts). Nuclear Medicine Communications 1999;20:946.
5. Zimmer AM, Spies M, Majewski W. Effects of drugs on in vivo RBC labelling: a proposed mechanism of inhibition. In Proceedings of the Second International Symposium of Radiopharmacy, Chicago, IL, 1981.
6. 99mTc-binding by red blood cells: concise communications. J Nucl Med 1983;24:894-7.
7. 99mTc. Nucl Med Commun 1982;3:155-61.
8. Sampson CB. Complications and difficulties in radiolabelling blood cells: a review. Nucl Med Commun 1996;17:648-58.
9. Borel JF (1981). The history of cyclosporin - A and its significance. In: Cyclosporin A (Edited by White DJG), p. 5-17. Elsevier Biomed. Press, Oxford.
10. Kahan BD, Flechner SM, Lorber MI, Jensen C, Golden D, Van Buren CT. Complications of cyclosporine therapy. World J Surg 1986;10:348-60.
11. Dross AA, Skopouli FN, Galanpoulou VK, Kitridou RC, Moutsopoulos HM. Cyclosporine therapy in patients with primary sjorgren's syndrome. Results at one year. Scan J Rheumatol 1986;61:246-9.
12. Owunwanne A, Shihab-Eldeen A. The effect of Cyclosporine-A on labelling blood cells with radiopharmaceuticals. Nucl Med and Biology 1996;23:1019-21.
13. 99mTechnetium red blood cells labeling efficiency in adults receiving chemotherapy and the clinical impact in pediatric oncology patients. Journal of Nucl Med Technol 1998;26(4):265-8.
14. 99mTc. Rev Esp Med Nuclear 1992;11(6):195-9.
15. AHFS, Drug Information 2000;906,1559,1580.
16. 99mTc ion to hemoglobin. J Nucl Med 1974;15:703-6.
17. 99mTc binding to the blood cell: Communication» J Nucl Med 1980;21:676-8.
18. 99mTechnetium red blood cell labeliing using the Ultratag® RBC in vitro Kit. J Nucl Med Technol 1995;23:22-5.
19. 99mTechnetium radiolabeling of red blood cells. J Nucl Med 1992;20:147-50.
20. 99mTechnetium labelling efficiency. J Nucl Med 1990;18:191-3.